Measurement of WT1-mRNA in Acute Myeloid Leukemia Patients
Not Applicable
Completed
- Conditions
- Acute Myeloid Leukemia
- Registration Number
- JPRN-jRCT1090220061
- Lead Sponsor
- Shuichi Miyawaki;Division of Hematology, Tokyo Metropolitan Ohtsuka Hospital.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Untreated, de novo AML patients, who are positi
ve for WT1-mRNA at diagnosis and without previous history of myelodysplastic syndrome.
Exclusion Criteria
AML cases who did not achieve complete remission after one-/two- course of remission-induction therapy.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Correlation between the comparison of WT1-mRNA of pre- with post-chemotherapy and 2-year relapse-free survival.
- Secondary Outcome Measures
Name Time Method Correlation between characteristics of the patients and the change of WT1-mRNA level and survival.